Preclinical Trial-on-Chip Hepatocellular Carcinoma & Metastasis Solution Powered CAR-T Development

Creative Biolabs provides Preclinical Trial-on-Chip solutions for hepatocellular carcinoma (HCC) and metastasis. These solutions address long preclinical timelines, challenges in modeling HCC and metastatic microenvironments, and difficulties in evaluating CAR-T infiltration and efficacy in solid tumors. Using biomimetic microfluidic models that replicate tumor architecture and immune interactions, our platform enables rapid, physiologically relevant assessment of CAR-T performance, supporting the optimization of CAR design, combination strategies, and overall therapeutic effectiveness.

Introduction

Preclinical evaluation of CAR-T therapies for solid tumors faces challenges due to complex tumor microenvironments, dense extracellular matrices, and metastatic niches. Recent studies demonstrate that microfluidic tumor-on-chip models can mimic patient-relevant HCC architecture and immune interactions, providing quantitative, real-time assessment of immune cell function. Integrating these models into CAR-T development reduces reliance on animal studies.

Fig.1 Targeting HCC with CAR T cell therapy.¹

Service

Creative Biolabs delivers a comprehensive "trial-on-chip" framework designed to transform your CAR-T candidate into a regulatory-ready therapeutic. Our solution bypasses the limitations of 2D cultures and murine models by providing an organotypic environment that simulates human HCC pathophysiology, including the bone marrow and metastatic liver niches. Clients benefit from precise measurements of T-cell extravasation, tumor infiltration, and cytotoxic kinetics within a multi-compartmental milieu.

• Assess CAR-T penetration and tumor-target engagement within dense extracellular matrix and heterogeneous tumor regions.
• Optimize CAR-T constructs, co-stimulatory domains, and cytokine support in a physiologically relevant setting.
• Evaluate potential off-target effects and immune suppression mechanisms before animal studies.

Discover How We Can Help - Request a Consultation to design a chip model.

What We Can Offer

Creative Biolabs provides an end-to-end service leveraging advanced microfluidics, 3D tumor cultures, and patient-derived organoids to model HCC and metastatic microenvironments. Core offerings include:

• Biomimetic tumor-on-chip platforms that replicate HCC tissue architecture and vascular interfaces.
• Patient-derived organoid integration for heterogeneity and personalized CAR-T assessment.
• High-resolution live-cell imaging and cytokine profiling for functional readouts.
• High-throughput evaluation of CAR-T variants, co-stimulatory designs, or combination therapies.

Our Workflow

Required Starting Materials:

CAR-T Candidates: Specific CAR-T constructs or sequences for production.

Tumor Cell Profiles: HCC/metastatic cell lines or patient-derived mononuclear cells with relevant target markers.

Final Deliverables:

Spatiotemporal Report: T-cell infiltration, migration, and killing efficiency.

Functional Index: Combined score of proliferation, activation, and cytokine profile.

Regulatory Data Package: 3D imaging and datasets.

Our Advantages

• Customized preclinical trial-on-chip platforms replicating primary HCC tumors and metastatic microenvironments for physiologically relevant CAR-T evaluation.
• Integration of patient-derived organoids and 3D tumor matrices to capture tumor heterogeneity and stromal interactions.
• Real-time monitoring of CAR-T infiltration, cytotoxicity, proliferation, and cytokine release with high-resolution imaging and multiplexed assays.
• Scalable platform design enabling high-throughput evaluation of multiple CAR-T constructs, co-stimulatory domains, or combination therapies.

FAQs

Partner with Us

Creative Biolabs provides the world's most advanced Preclinical Trial-on-Chip Solution for HCC and Metastasis, merging bioengineering with immunology to ensure your CAR-T assets are more than just binders. They are clinically viable cures. We enable you to test a patient's own cancer cells against multiple therapy designs in a realistic human niche before treatment ever begins. For detailed technical specifications or to discuss a custom niche architecture for your asset, please contact our team.

Reference

1. Aggeletopoulou, Ioanna et al. "Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?" International journal of molecular sciences vol. 25,5 2631. 23 Feb. 2024. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/ijms25052631